[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fallopian-tube-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fallopian-tube-carcinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,42,79,91,139,164,198,239,258,280,304,336,358,378],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100054194","phase-2-igfbp-2-vaccine-to-prevent-ovarian-cancer-progression-in-patients-with-serologic-detection-of-recurrence-100054194",false,"NCT07495124","IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence","A Phase II Study of (IGFBP-2) Vaccine to Prevent Progression After Serologic Detection of Recurrent Ovarian Cancer","Inclusion Criteria:\n\n* Have a diagnosis of ovarian, fallopian tube, or primary peritoneal cancer who have received systemic chemotherapy including platinum-based chemotherapy\n* Have a cancer antigen 125 (CA-125) that normalized after first-line therapy\n* CA-125 increased to more than twice the upper limit of normal or two times the nadir value after most recent second or later line of treatment\n* Have no measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Ascites and pleural effusions are not measurable disease, if asymptomatic\n* All patients who are having sex that can lead to pregnancy must agree to contraception for the duration of the study (end of one year follow up). Note: Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or postmenopausal\n* Have estimated life expectancy of at least 3 months\n* Be willing and able to provide written informed consent\u002Fassent for the trial\n* Be ≥ 18 years of age on day of signing informed consent\n* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale\n* White blood cell (WBC) ≥ 3000\u002Fmm\\^3 (performed within 14 days of treatment initiation)\n* Hemoglobin (Hgb) ≥ 10 g\u002Fdl (performed within 14 days of treatment initiation)\n* Hematocrit (Hct) ≥ 28% (performed within 14 days of treatment initiation)\n* Serum creatinine ≤ 2.0 mg\u002Fdl or creatinine clearance \\> 60 mL\u002Fmin (performed within 14 days of treatment initiation)\n* Total bilirubin ≤ 2.5 mg\u002Fdl (performed within 14 days of treatment initiation)\n* Aspartate aminotransferase (AST) ≤ 3 times upper limit of normal (ULN) (performed within 14 days of treatment initiation)\n* Blood glucose \\\u003C 1.5 ULN (performed within 14 days of treatment initiation)\n\nExclusion Criteria:\n\n* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of treatment (i.e., day 1)\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (if dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment\n\n  * Short-term administration of systemic steroids (i.e., for allergic reactions or the management of immune-related adverse events \\[irAEs\\]) is allowed\n* Has symptomatic ascites or pleural effusions\n* History of borderline or low malignant potential ovarian cancer\n* Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., ≤ grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier\n* Has had prior chemotherapy, biologic therapy, targeted small molecule therapy, hormonal therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ≤ grade 1 or at baseline) from adverse events due to a previously administered agent\n\n  * Note: Patients with ≤ grade 2 neuropathy are an exception to this criterion and may qualify for the study\n  * Note: If a patient received major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting therapy\n* Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 14 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\n* Has an active infection requiring systemic therapy\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator\n* Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment\n* Clinically significant cardiovascular disease\n* Known severe hypersensitivity reactions to carboplatin ≥ grade 3, any history of anaphylaxis, or uncontrolled asthma\n* Patients with any contraindication to receiving recombinant human granulocyte macrophage-colony stimulating factor (rhuGM-CSF) based products\n* Has a known history of human immunodeficiency virus (HIV) (HIV 1\u002F2 antibodies)\n* Has known active hepatitis B (e.g., hepatitis B virus surface antigen \\[HBsAg\\] reactive) or hepatitis C (e.g., hepatitis c virus \\[HCV\\] ribonucleic acid \\[RNA\\] \\[qualitative\\] is detected)\n* Has received a live vaccine or live-attenuated vaccine within 30 days of planned start of study therapy. Administration of killed vaccines is allowed\n\n  * Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed","FEMALE","18 Years",{"count":19,"type":20},26,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial studies how well giving the insulin-like growth factor binding protein 2 \\[pUMVC3-hIGFBP-2 multi-epitope plasmid deoxyribonucleic acid (DNA) (IGFBP-2)\\] vaccine after one dose of carboplatin works to stop ovarian cancer from growing, spreading, or getting worse (progressing) in patients whose cancer recurrence is detected only in the blood (serologic detection) following treatment with platinum chemotherapy. IGFBP-2 is a protein found in ovarian cancer cells. The IGFBP-2 vaccine may help the body build an effective immune response to kill tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It has been shown to activate parts of the immune system that may act against tumors. Giving the IGFBP-2 vaccine after a single dose of carboplatin may be an effective way to stop ovarian cancer from progressing in patients with serologic detection following treatment with platinum chemotherapy.",[26,27,28],"Fallopian Tube Carcinoma","Ovarian Carcinoma","Primary Peritoneal Carcinoma","NOT_YET_RECRUITING","2026-07-09",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":20},"2026-10-01",{"date":37,"type":20},"2028-09-30",{"name":39,"class":40},"University of Washington","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":41},"100639206","phase-1-dual-targeting-car-nk-cells-for-recurrent-ovarian-cancer-msln-fr-muc16-pt2-100639206","NCT07617753","Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2","A Phase 1\u002F2, Open-Label, Biomarker-Assigned Study of Dual-Targeting CAR-NK Cells Directed Against Mesothelin (MSLN), Folate Receptor Alpha (FRα\u002FFOLR1), and\u002For MUC16 (CA125) in Patients With Recurrent or Refractory High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","DUAL-OV-CAR-NK","Inclusion Criteria:\n\n* Histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (high-grade serous preferred).\n* Recurrent or refractory disease after at least 2 prior systemic treatment lines (including a platinum-based regimen unless contraindicated).\n* Measurable disease per RECIST v1.1.\n* Tumor expresses at least two of the following targets above protocol-defined threshold: MSLN, FRalpha (FOLR1), MUC16 (CA 125) (archival or fresh biopsy).\n* ECOG performance status 0-1.\n* Adequate organ function : ANC \\>= 1.0 x 10\\^9\u002FL; platelets \\>= 75 x 10\\^9\u002FL; hemoglobin \\>= 8 g\u002FdL; AST\u002FALT \\\u003C= 3 x ULN (\\\u003C= 5 x ULN with liver metastases); total bilirubin \\\u003C= 1.5 x ULN; creatinine clearance \\>= 50 mL\u002Fmin.\n* Negative pregnancy test for women of childbearing potential; agreement to use effective contraception through 12 months post-infusion (or per local gene-therapy guidance).\n* Able to comply with study procedures and follow-up schedule; written informed consent.\n\nExclusion Criteria:\n\n* Prior gene-modified cellular therapy (e.g., CAR-T, CAR-NK) within 6 months (or any prior therapy directed to the same target, per protocol).\n* Active central nervous system (CNS) metastases or carcinomatous meningitis requiring therapy.\n* Uncontrolled infection, including active tuberculosis; or clinically significant, uncontrolled viral infection.\n* Known HIV infection with uncontrolled viremia; active hepatitis B or hepatitis C with detectable viral load (testing required at screening).\n* Clinically significant cardiovascular disease (e.g., recent myocardial infarction, uncontrolled arrhythmia, NYHA Class III\u002FIV heart failure).\n* Active autoimmune disease requiring systemic immunosuppression within 30 days (physiologic steroid replacement allowed).\n* Concurrent anti-cancer therapy (chemotherapy, targeted therapy, radiotherapy) not permitted within a protocol-defined washout period.\n* Major surgery within 4 weeks prior to lymphodepletion (except minor procedures)\n* Pregnant or breastfeeding.\n* Any condition that, in the investigator's judgment, would increase risk (e.g., severe pulmonary disease) or interfere with study interpretation.","75 Years",{"count":52,"type":20},36,[54,23],"PHASE1","This Phase 1\u002F2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer. At screening, each participant's tumor is assessed for expression of Mesothelin (MSLN), Folate Receptor alpha (FRalpha\u002FFOLR1), and MUC16 (CA 125). Participants are assigned to the dual-target CAR-NK product that best matches their tumor antigen profile to reduce the risk of antigen escape.",[57,28,26,58],"Epithelial Ovarian Cancer","Recurrent or Refractory Disease After Standard Therapies",[60,61,62,63,64,65,66,67],"CAR-NK","Dual targeting","Mesothelin (MSLN)","Folate Receptor alpha","MUC16","Intraperitoneal administration","Adoptive cell therapy","Ovarian cancer","RECRUITING","2026-05-25",{"date":71,"type":33},"2026-06-01",{"date":73,"type":33},"2026-03-02",{"date":75,"type":20},"2028-03-17",{"name":77,"class":78},"Beijing Biotech","INDUSTRY",{"id":80,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":24,"conditions":83,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":90,"locationsCount":41},"100631011",{"count":19,"type":20},[23],[26,27,28],"2026-05-22",{"date":86,"type":33},"2026-05-26",{"date":88,"type":20},"2026-07-01",{"date":37,"type":20},{"name":39,"class":40},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":98,"minAge":17,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":41},"100614857","phase-2-the-cancer-connected-access-and-remote-expertise-beyond-walls-program-to-provide-in-home-cancer-treatment-and-improve-treatment-satisfaction-in-cancer-patients-living-in-the-florida-panhandle-and-surrounding-areas-100614857","NCT07285044","The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas","Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas","Inclusion Criteria:\n\n* Patient has had adequate tolerability of their clinical standard of care treatment, in the opinion of their treating physician, and no clinically significant drug-related reactions occurred prior to consent\n* Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) Food and Drug Administration (FDA)-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. National Comprehensive Cancer Network \\[NCCN\\], American Society of Clinical Oncology \\[ASCO\\], American Society of Hematology \\[ASH\\], etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines\n* A social stability screener, used per standard of care, indicates patient is appropriate to participate in the CCBW program\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3 at the discretion of the treating physician\n* Female or male patients age \\>= 18 years at the time of consent\n* Willing and able to comply with the study protocol in the investigator's judgement\n* Patients with histologically confirmed malignancy who are currently receiving treatment with one of the eligible treatment regimens. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis alone: histologic confirmation is not required.\n\n  * Note: patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving hormonal or immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Co-administration with hormonal agents such as anti-androgens, poly(ADP-ribose) polymerase (PARP) inhibitors, oral gonadotrophin releasing hormone (GnRh) antagonists, estrogens, selective estrogen receptor modulators (SERMs), or aromatase inhibitors are allowed, however combinations of oral regimens only are not permitted. Patients may receive any combination of any listed medications or regimens\n  * Eligible disease cancer types:\n\n    * Amyloidosis\n    * Basal cell carcinoma\n    * Biliary\n    * Bladder\n    * Breast\n    * Cervical\n    * Colorectal\n    * Endometrial\n    * Fallopian tube\n    * Gastroesophageal\n    * Glioblastoma\n    * Head and neck\n    * Hepatocellular\n    * Hodgkin lymphoma\n    * Lung\n    * Mantle cell lymphoma\n    * Merkle cell carcinoma\n    * Multiple myeloma\n    * Melanoma\n    * Myelodysplastic syndrome\n    * Ovarian\n    * Pancreatic\n    * Peritoneal\n    * Prostate\n    * Renal cell carcinoma\n    * Squamous cell carcinoma\n    * Urothelial carcinoma\n  * Eligible regimens\n\n    * Atezolizumab +\u002F- bevacizumab\n    * Avelumab\n    * Bevacizumab\n    * Bortezomib\n    * Cemiplimab\n    * Daratumumab +\u002F- bortezomib\n    * Darbepoetin alpha\n    * Degarelix\n    * Denosumab (Xgeva)\n    * Durvalumab\n    * Fluorouracil +\u002F- bevacizumab\n    * Fulvestrant\n    * Goserelin\n    * Ipilimumab +\u002F- Nivolumab\n    * Lanreotide\n    * Leuprolide\n    * Nivolumab\n    * Nivolumab + relatlimab\n    * Octreotide\n    * Pembrolizumab\n    * Pertuzumab +\u002F- trastuzumab\n    * Trastuzumab +\u002F- pertuzumab\n    * Zoledronic acid (Zometa)\n* Willingness to follow birth control requirements for females and males of reproductive potential\n* Resides within the Florida Panhandle and surrounding area serviced by the at-home healthcare supplier utilized for the study and a paramedic network\n* Patient's residence has an existing Wi-Fi connection or can be connected using using a mobile Wi-Fi device provided as part of the program so as to enable a reliable connection with the remote CCBW Command Center at Mayo Clinic\n* Patients who, according to documentation from their treating provider, plan to continue the eligible treatment regimen they are currently prescribed for \\>= 12 weeks from the time of registration\n* Provide written informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.\n\n  * Note: oral concomitant medications for oncologic indications will be maintained per standard of care treatment and not considered part of the trial. Any nononcologic medication, regardless of route of administration will be maintained per standard of care treatment and also not considered part of the trial; therefore, patients receiving oral anti-cancer or other medications per standard of care treatment in addition to any of the medications listed are considered eligible for this trial\n* Individuals who require continuous (24\u002F7) assistance with daily living and are unable to independently manage the technology required for study participation, unless a caregiver is available and willing to provide consistent support throughout the study\n* Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)","ALL",{"count":100,"type":20},27,[23],"This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.",[104,105,106,107,108,109,110,111,26,112,113,114,115,116,117,118,119,120,121,122,123,124,27,125,28,126,127,128,129],"Amyloidosis","Basal Cell Carcinoma","Biliary Tract Carcinoma","Bladder Carcinoma","Breast Carcinoma","Cervical Carcinoma","Colorectal Carcinoma","Endometrial Carcinoma","Gastroesophageal Junction Carcinoma","Glioblastoma","Head and Neck Carcinoma","Hematopoietic and Lymphatic System Neoplasm","Hepatocellular Carcinoma","Hodgkin Lymphoma","Lung Carcinoma","Malignant Solid Neoplasm","Mantle Cell Lymphoma","Melanoma","Merkel Cell Carcinoma","Multiple Myeloma","Myelodysplastic Syndrome","Pancreatic Carcinoma","Prostate Carcinoma","Renal Cell Carcinoma","Squamous Cell Carcinoma","Urothelial Carcinoma","2026-05-15",{"date":132,"type":33},"2026-05-18",{"date":134,"type":33},"2025-12-18",{"date":136,"type":20},"2026-12-18",{"name":138,"class":40},"Mayo Clinic",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":21,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":41},"100332134","phase-1-serial-imaging-of-the-novel-radiotracer-18f-fluorthanatrace-18f-ftt-by-petctf-100332134","NCT03604315","Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET\u002FCTF","Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET\u002FCT","Inclusion Criteria:\n\n* History of known or suspected solid tumor.\n* At least one lesion ≥ 1.0 cm that is seen on standard imaging (e.g. computed tomography \\[CT\\], magnetic resonance imaging \\[MRI\\], ultrasound, fludeoxyglucose \\[FDG\\] PET\u002FCT).\n\nExclusion Criteria:\n\n* Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential \\\u003C 2 weeks prior to screening as standard of care.\n* Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.\n* Any current medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.",{"count":147,"type":20},300,[54],"This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)\u002Fcomputed tomography (CT) works in patients with solid tumors. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET\u002FCT uses a scanner to make detailed, computerized pictures of areas inside the body. PET\u002FCT with Fluorine F 18 fluorthanatrace may allow more tumor cells to be found in patients with ovarian, fallopian tube, or primary peritoneal cancer.",[108,26,27,28,151,152,153,154],"Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Solid Neoplasm","2026-04-10",{"date":157,"type":33},"2026-04-15",{"date":159,"type":33},"2018-12-18",{"date":161,"type":20},"2027-06-30",{"name":163,"class":40},"M.D. Anderson Cancer Center",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":21,"phases":173,"briefSummary":175,"conditions":176,"keywords":183,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100570692","revitalize-rct-to-reduce-fatigue-in-adults-with-ovarian-cancer-on-parp-inhibitors-100570692","NCT06710548","REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors","Randomized Trial of REVITALIZE: A Telehealth Intervention to Reduce Fatigue Interference Among Adults With Advanced Ovarian Cancer on PARP Inhibitors","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years) with ovarian, fallopian tube, or primary peritoneal cancers (hereafter ovarian cancer) who have completed primary therapy (surgery and chemotherapy).\n* Treated with a PARP inhibitor as maintenance therapy for ≥2 months and plan to continue for at least 7 months.\n* English-speaking.\n* Mean fatigue severity level ≥4 on the first three items of the Fatigue Symptom Inventory.\n* ECOG performance status of 0-2.\n* Willing to use a wireless pill bottle for PARP inhibitor medication.\n\nExclusion Criteria:\n\n* Untreated clinical condition or comorbid condition that pre-dates PARP inhibitor use and could explain fatigue, as evaluated by their treating oncologist.\n* Patients with severe psychiatric conditions (e.g. untreated trauma unrelated to cancer, high or imminent suicidality) as evaluated by their treating oncologist, which require more intensive psychiatric treatment than the study can provide.\n* Patients with cognitive conditions (e.g. dementia), determined by their treating oncologist, such that they could not provide informed consent or complete the study procedures.\n* Inability to complete the first questionnaire within one week of consent.",{"count":172,"type":20},240,[174],"NA","The purpose of this study is to see whether a supportive intervention (REVITALIZE) reduces fatigue and its impact on daily life and activities for participants with ovarian cancer taking PARP inhibitors.\n\nThe name of the study groups in this research study are:\n\n1. REVITALIZE\n2. Educational Materials",[177,178,26,179,180,181,182],"Ovarian Cancer","Advanced Ovarian Carcinoma","Primary Peritoneal Cancer","PARP Inhibitor","Fatigue Related to Cancer Treatment","Fatigue in Cancer Survivors",[177,178,184,179,185,186,182,187],"Advanced Ovarian Cancer","Fallopian Tube Cancer","Fatigue related to cancer treatment","PARP inhibitor","2026-04-07",{"date":190,"type":33},"2026-04-13",{"date":192,"type":33},"2025-03-17",{"date":194,"type":20},"2029-01-31",{"name":196,"class":40},"Dana-Farber Cancer Institute",6,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":98,"minAge":17,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":21,"phases":207,"briefSummary":208,"conditions":209,"keywords":216,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":238},"100538389","phase-2-study-of-acute-normovolemic-hemodilution-anh-in-people-with-ovarian-cancer-who-are-having-cytoreductive-surgery-100538389","NCT06290193","Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery","A Prospective Randomized Trial of Acute Normovolemic Hemodilution (ANH) in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer","Inclusion Criteria:\n\n* Adults (≥18 years)\n* BLOODS score ≥2 as calculated by surgeon\n* High preoperative suspicion (or diagnosis) of advanced primary epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (stage IIIC or IV), as determined by CT or MRI of the abdomen\u002Fpelvis\n* Planned for exploratory laparotomy and primary or interval cytoreductive surgery\n* Preoperative hemoglobin concentration ≥10 mg\u002Fdl within 45 days of surgery\n* Patients scheduled for cytoreductive surgery, with or without other planned procedures o Note: Patients scheduled for only diagnostic laparoscopy should not be included\n\nExclusion Criteria:\n\n* A history of active coronary artery disease\n\n  o Patients with a history of coronary artery disease will be eligible if they have had a cardiac stress study showing no reversible ischemia and normal LV function within 45 days of surgery.\n* A history of cerebrovascular disease\n* A history of congestive heart failure\n* A history of uncontrolled hypertension\n* A history of restrictive or obstructive pulmonary disease\n* A history of renal dysfunction (Cr \\>1.6 mg\u002Fdl)\n* Abnormal coagulation parameters (INR \\>1.5 not on coumadin, or platelet count \\\u003C100,000 mcL)\n* Presence of active infection\n* Evidence of hepatic metabolic disorder (bilirubin \\>2 mg\u002Fdl, ALT \\>75 U\u002FL in the absence of biliary tract obstruction)\n* Preoperative autologous blood donation within last 30 days or plan to donate autologous blood prior to surgery\n* Refusal to accept allogenic or autologous blood transfusion\n* Patients scheduled for cytoreductive surgery with planned Hyperthermic Intraperitoneal Chemotherapy (HIPEC)",{"count":206,"type":20},86,[23],"Participants will be scheduled for primary cytoreductive surgery as part of their standard care. Before surgery, participants will be assigned by chance to a study group. Depending on which group they are in, they will receive either acute normovolemic hemodilution\u002FANH during surgery or standard surgical management during surgery. The researchers think acute normovolemic hemodilution\u002FANH may decrease the need for allogenic blood transfusion\u002FABT in people having primary cytoreductive surgery.",[177,26,27,210,211,212,213,214,185,215],"Peritoneal Carcinoma","Ovarian Cancer Stage IIIC","Fallopian Tube Cancer Stage IIIC","Ovarian Cancer Stage IV","Fallopian Tube Cancer Stage IV","Peritoneal Cancer",[217,218,219,220,221,222,223,224,225,226,227,228,229],"ovarian cancer","ovarian carcinoma","ovarian cancer stage IIIC","ovarian cancer stage IV","fallopian tube cancer","fallopian tube carcinoma","fallopian tube cancer stage IIIC","fallopian tube cancer stage IV","peritoneal cancer","peritoneal carcinoma","Acute Normovolemic Hemodilution","Memorial Sloan Kettering Cancer Center","23-392","2026-03-31",{"date":232,"type":33},"2026-04-01",{"date":234,"type":33},"2024-02-23",{"date":236,"type":20},"2029-02-23",{"name":228,"class":40},7,{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":47,"acronym":48,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":245,"targetDuration":4,"studyType":21,"phases":246,"briefSummary":55,"conditions":247,"keywords":248,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":41},"100629921","phase-1-dual-targeting-car-nk-cells-for-recurrent-ovarian-cancer-msln-fr-muc16-100629921","NCT07480954","Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","Inclusion Criteria:\n\n* Histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (high-grade serous preferred).\n* Recurrent or refractory disease after at least 2 prior systemic treatment lines (including a platinum-based regimen unless contraindicated).\n* Measurable disease per RECIST v1.1.\n* Tumor expresses at least two of the following targets above protocol-defined threshold: MSLN, FRalpha (FOLR1), MUC16 (CA 125) (archival or fresh biopsy).\n* ECOG performance status 0-1.\n* Adequate organ function (example): ANC \\>= 1.0 x 10\\^9\u002FL; platelets \\>= 75 x 10\\^9\u002FL; hemoglobin \\>= 8 g\u002FdL; AST\u002FALT \\\u003C= 3 x ULN (\\\u003C= 5 x ULN with liver metastases); total bilirubin \\\u003C= 1.5 x ULN; creatinine clearance \\>= 50 mL\u002Fmin.\n* Negative pregnancy test for women of childbearing potential; agreement to use effective contraception through 12 months post-infusion (or per local gene-therapy guidance).\n* Able to comply with study procedures and follow-up schedule; written informed consent.\n\nExclusion Criteria:\n\n* Prior gene-modified cellular therapy (e.g., CAR-T, CAR-NK) within 6 months (or any prior therapy directed to the same target, per protocol).\n* Active central nervous system (CNS) metastases or carcinomatous meningitis requiring therapy.\n* Uncontrolled infection, including active tuberculosis; or clinically significant, uncontrolled viral infection.\n* Known HIV infection with uncontrolled viremia; active hepatitis B or hepatitis C with detectable viral load (testing required at screening).\n* Clinically significant cardiovascular disease (e.g., recent myocardial infarction, uncontrolled arrhythmia, NYHA Class III\u002FIV heart failure).\n* Active autoimmune disease requiring systemic immunosuppression within 30 days (physiologic steroid replacement allowed).\n* Concurrent anti-cancer therapy (chemotherapy, targeted therapy, radiotherapy) not permitted within a protocol-defined washout period.\n* Major surgery within 4 weeks prior to lymphodepletion (except minor procedures).",{"count":52,"type":20},[54,23],[57,28,26,58],[60,61,62,63,249,65,66,67],"MUC16 (CA 125)","2026-03-14",{"date":252,"type":33},"2026-03-18",{"date":254,"type":33},"2026-02-04",{"date":256,"type":20},"2028-05-17",{"name":77,"class":78},{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":264,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":267,"phases":4,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":41},"100308555","prospective-cohort-study-of-germline-variant-carriers-with-brca1-or-brca2-100308555","NCT03296826","Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2","Inclusion Criteria:\n\n1. Women carrying BRCA1\u002F2 variants (those with either BRCA1 or BRCA2 variants, or those carrying both variants) and women carrying a variant of uncertain significance (VUS).\n2. Women who have received sufficient genetic counseling at any medical institution, prior to enrollment to the study.\n3. Women who provide consent should be 20 years of age or older.\n4. Women who provide written consent.\n\nExclusion Criteria:\n\n1. Women without ovarian or fallopian tube cancer at the time of informed consent.\n2. Women previously diagnosed with ovarian, fallopian tube, or peritoneal cancer, and not excluding those with a personal history of breast cancer development.\n3. Other individuals considered inappropriate for involvement in this study by the investigator.","20 Years",{"count":266,"type":20},600,"OBSERVATIONAL","To determine the incidence and risk factors in the development of ovarian, fallopian tube, and peritoneal cancers in Japanese women carrying Breast Cancer Susceptibility Gene (BRCA)1\u002F2 variants.",[270,27,26,210],"BRCA1 and\u002For BRCA2 Variant Carriers","2026-01-30",{"date":273,"type":33},"2026-02-03",{"date":275,"type":33},"2017-11-08",{"date":277,"type":20},"2032-03-31",{"name":279,"class":40},"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":21,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":303},"100553898","phase-2-cryocompression-with-or-without-cilostazol-for-the-prevention-of-paclitaxel-induced-neuropathy-in-patients-with-gynecological-cancers-100553898","NCT06492070","Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers","Prevention of Paclitaxel-Induced Peripheral Neuropathy: Randomized Trial of Cryocompression With or Without Cilostazol","Inclusion Criteria:\n\n* INCLUSION CRITERIA FOR ARMS A and B:\n* Age 18 years or older\n* Diagnosis of uterine, ovarian\u002Ffallopian tube\u002Fprimary peritoneal, cervical, or vulvar cancer and planned chemotherapy regimen of 6-9 cycles of paclitaxel and carboplatin or cisplatin with or without VEGF inhibition, with or without immunotherapy, and with or without HER2-directed therapy\n* Eastern Cooperative Oncology Group performance status from 0 to 2\n* ARM C: Age 18 years or older\n* ARM C: Diagnosis of uterine, ovarian\u002Ffallopian tube\u002Fprimary peritoneal, cervical, or vulvar cancer and completion of 6-9 cycles of a chemotherapy regimen consisting of paclitaxel and carboplatin or cisplatin with or without VEGF inhibition, with or without immunotherapy, and with or without HER2-directed therapy within the last 3 months\n* ARM C: Eastern Cooperative Oncology Group performance status from 0 to 2\n\nExclusion Criteria:\n\n* EXCLUSION CRITERIA FOR ARMS A and B:\n* Any patient unable and\u002For unwilling to cooperate with all study protocols\n* Previous treatment with paclitaxel\n* Patients with baseline pre-chemotherapy neuropathy requiring pharmacologic treatment\n* Diabetes mellitus with hemoglobin A1c \\>7.0\n* Hepatic impairment, moderate to severe (Class B \\& C by Child-Pugh score)\n\n  * Slight or moderate malignant ascites alone will not be considered indicative of hepatic impairment in the absence of other evidence of hepatic disease\n* Raynaud's phenomenon\n* Active wounds on the hands or feet\n* High risk uncontrolled arrhythmias\n* Ischemic heart disease\n* Inadequate bone marrow function with white blood count \\\u003C 4,000\u002Fmm\\^3 and platelet count \\\u003C 100,000\u002Fmm\\^3\n* Inadequate liver function with serum total bilirubin \\>= 1.5mg\u002FdL\n* Inadequate renal function with serum creatinine \\>= 1.5mg\u002FdL\n* On one or more antiplatelet therapies excluding acetylsalicylic acid\n* Hypersensitivity (e.g. anaphylaxis, angioedema) to cilostazol or any components of cilostazol\n* Pregnant and nursing patients\n\n  * Patients enrolled in this study who have the potential to become pregnant (have an intact uterus, ovary(ies), and fallopian tube(s), have not entered menopause, and have regular menses) are required to utilize reliable contraception such as celibacy, hormonal contraception (oral pills, implant, injection, ring or patch), intrauterine device (IUD), condom and\u002For diaphragm with spermicide\n* Incarcerated patients\n* Patients unable to consent for themselves, due to cognitive impairment or other reason\n* Patients with contraindications to cilostazol\n* Any patient who does not meet criteria to receive chemotherapy\n* ARM C: Any patient unable and\u002For unwilling to cooperate with all study protocols\n* ARM C: Previous treatment with paclitaxel\n* ARM C: Patients with baseline pre-chemotherapy neuropathy requiring pharmacologic treatment\n* ARM C: Diabetes mellitus with hemoglobin A1c \\>7.0\n* ARM C: Pregnant patients\n* ARM C: Incarcerated patients\n* ARM C: Patients unable to consent for themselves, due to cognitive impairment or other reason",{"count":288,"type":20},70,[23],"The phase II trial evaluates the effectiveness of cryocompression therapy alone or in combination with cilostazol in preventing paclitaxel-induced peripheral neuropathy (numbness, pain or tingling in the feet and hands) for patients with gynecologic cancers. Peripheral neuropathy is a common side effect of many chemotherapeutic agents, including paclitaxel. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Cryocompression is a therapy that combines compression garments or dressings with cooling of the treated area. Cilostazol is in a class of medications called platelet-aggregation inhibitors (antiplatelet medications). It works by improving blood flow to the legs. Giving cilostazol together with cryocompression may be safe and tolerable in treating patients with gynecological cancers.",[109,26,119,292,27,28,293],"Malignant Uterine Neoplasm","Vulvar Carcinoma","2025-08-20",{"date":296,"type":33},"2025-08-27",{"date":298,"type":33},"2024-08-01",{"date":300,"type":20},"2027-12-31",{"name":302,"class":40},"Emory University",3,{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":98,"minAge":17,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":267,"phases":4,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":335},"100443825","oracle-observation-of-residual-cancer-with-liquid-biopsy-evaluation-100443825","NCT05059444","ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation","ORACLE","Inclusion Criteria:\n\n* Age \\> 18 years old AND\n* Initial treatment is given with curative\u002Fradical intent AND\n* Are planning to undergo regular follow-up and monitoring for cancer recurrence per standard of care at the enrolling site AND\n* Provided written informed consent to participate in the study AND\n* Are willing to have de-identified clinical data shared with investigators at regular intervals as outlined in the study protocol and informed consent AND\n* Are willing to provide blood samples at enrollment and at subsequent clinical visits coinciding with standard of care follow-up, for up to 5 years as outlined in the study protocol and informed consent AND\n* Have at least one Landmark blood sample\n\nHave a histologically confirmed Index Cancer that qualifies for inclusion, defined as:\n\nPrimary Study Cohorts\n\n* Cohort 1: Cohort 1: Muscle invasive carcinoma of the bladder, ureter, or renal pelvis (stage II-III),\n* Cohort 2: Cohort 2: Non-small cell lung cancer (stage IB-III):\n\nCohort 2A: Resectable OR Cohort 2B: Unresectable,\n\n* Cohort 3: Invasive breast carcinoma with hormone receptor (e.g. estrogen receptor (ER) and progesterone receptor (PR) expression) and human epidermal growth factor receptor 2 (HER2) status known and one the following:\n\nCohort 3A: High-risk2 HER2+ breast cancer (any ER, PR status allowed) OR Cohort 3B: High-risk2 triple negative breast cancer (TNBC) OR Cohort 3C: High-risk3 HR-positive\u002FHER2-negative invasive breast carcinoma,\n\n* Cohort 4: Stage IIB-III cutaneous melanoma or limited (resectable) stage IV melanoma treated with curative intent,\n* Cohort 5: Esophageal or gastroesophageal junction carcinoma (stage II-III),\n* Cohort 6: Gastric adenocarcinoma (stage II-III),\n* Cohort 7: Pancreatic adenocarcinoma that is has been surgically resected or is eligible for surgical resection,\n* Cohort 8: Invasive squamous cell carcinoma of the head and neck (Includes stage I-IVB oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, nasal cavity, and paranasal sinus cancers),\n* Cohort 9: High-risk epithelial ovarian or Fallopian tube carcinoma (Defined as FIGO stage IC-III or stage IA-IB that has high grade or clear cell histology),\n* Cohort 10: High-risk endometrial carcinoma (Defined as 2023 FIGO Stage II-III),\n* Cohort 11: High-risk renal cell carcinoma (Defined as high grade (grade 3-4) stage II, stage III or limited (resectable) stage IV treated with curative intent)\n\nExploratory Cohort\n\n* Cohort 12: Pathologically confirmed adenocarcinoma of the rectum (located up to 15 cm from the anal verge) that is undergoing or underwent a preoperative chemotherapy- or immunotherapy- containing regimen\n\nExclusion Criteria:\n\n* History of allogeneic organ or tissue transplant\n* Index cancer has predominantly neuroendocrine histology\n* History of another primary cancer diagnosed within 3 years of enrollment, with the exception that in situ cancers, non-melanoma skin carcinomas, localized low- or intermediate risk prostate cancers, and stage I papillary thyroid carcinoma, and participants with bilateral\u002Fmultifocal tumors within the same organ (for example, bilateral breast cancer) are allowed if diagnosed within 3 years of enrollment\n* Known distant metastasis at time of enrollment (with the exception of participants with limited\u002Fresectable stage IV cutaneous melanoma or RCC)",{"count":312,"type":20},2020,"The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.",[107,315,316,317,318,319,320,112,321,322,323,324,26,111,127,325],"Ureter Carcinoma","Renal Pelvis Carcinoma","Non-small Cell Lung Cancer","Invasive Breast Carcinoma","Cutaneous Melanoma","Esophageal Carcinoma","Gastric Adenocarcinoma","Pancreatic Adenocarcinoma","Squamous Cell Carcinoma of the Head and Neck","Epithelial Ovarian Carcinoma","Rectal Adenocarcinoma","2025-08-18",{"date":328,"type":33},"2025-08-22",{"date":330,"type":33},"2021-09-07",{"date":332,"type":20},"2029-08",{"name":334,"class":78},"Guardant Health, Inc.",57,{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":21,"phases":345,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":41},"100581139","phase-1-sct-001-car-t-cells-therapy-for-relapsed-and-refractory-ovarian-cancer-100581139","NCT06846424","SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer","A Clinical Study to Evaluate the Safety and Tolerability of SCT-001 CAR-T Cells in Patients with Recurrent and Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Peritoneal Cancer.","Inclusion Criteria:\n\n* Subjects must meet all of the following criteria for admission to this study:\n\nAge≥ 18 years old;\n\n* ECOG performance status score: 0\\~2 points or KPS score≥70 points;\n* Relapsed or refractory epithelial ovarian, fallopian tube and peritoneal cancer confirmed by histology or cytology and have failed, are intolerant or have no standard treatment after standard therapy;\n* Tumor tissue specimens or tumor samples can be obtained by tumor biopsy and other methods;\n* Immunohistochemistry (IHC) staining confirmed that the tumor cells had positive TAG-72 expression (positive definition: \\>). IHC staining intensity of 1% tumor cells ≥2+);\n* Estimated survival time of more than 3 months;\n* At least one evaluable tumor lesion according to RECIST 1.1;\n* Prior to treatment, major organ function met the following criteria (no blood transfusion, long-acting EPO, long-acting G-CSF therapy within 14 days prior to study drug administration, in the case of short-acting EPO, short-acting G-CSF, this criterion can be shortened to 7 days):\n* complete blood count: Absolute neutrophil count (ANC) ≥1.5×109\u002FL,, Absolute lymphocyte count (ALC) ≥ 0.5×109\u002FL; hemoglobin (HGB) ≥ 80 g\u002FL; Platelets (PLT) ≥ 75×109\u002FL;\n* Renal: serum creatinine ≤1.5× upper limit of normal range (ULN);\n* Liver: total bilirubin ≤ 1.5× ULN (including patients with liver metastases or liver cancer), AST and ALT ≤ 2.5× ULN (liver metastases ≤5×ULN);\n* Coagulation: International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5× ULN, partially activated thromboplastin time (APTT) ≤ 1.5× ULN;\n* Must be using adequate contraception during the study and for 6 months after the end of the study, have a negative serum pregnancy test within 7 days prior to proposed enrollment in the study, and must be a non-lactating subject.\n\nExclusion Criteria:\n\n* Subjects who meet any of the following criteria will not be admitted to this study:\n* Those who are allergic to any component of SCT-001 CAR-T cell injection;\n* Received anti-tumor therapy such as chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy, etc., or participated in other clinical trials and received 5 half-lives of therapeutic drugs within 4 weeks prior to the first use of the study drug (4 weeks or 5 half-lives, whichever is shorter);\n* Received treatment with traditional Chinese medicine or modern Chinese medicine preparations with anti-tumor indications in the label within 14 days before the first dose;\n* The adverse reactions of previous anti-tumor therapy have not recovered to NCI CTCAE v5.0 grade evaluation ≤ grade 1 (except for toxicity that the investigator judges has no safety risk such as alopecia);\n* Surgical procedure within 4 weeks prior to treatment or has not fully recovered from any previous invasive procedure;\n* Central nervous system metastases or meningeal metastases with clinical symptoms, or other evidence that the subject's central nervous system metastases or meningeal metastases have not been controlled, and are judged by the investigator to be unsuitable for enrollment;\n* Those with active infection (NCI CTCAE v5.0≥ grade 2) or any other person with suspected risk of infection as assessed by the investigator;\n* Has a history of autoimmune disease, immunodeficiency, including a positive HIV test, or has other acquired, congenital immunodeficiency diseases, or has a history of organ transplantation;\n* Subjects with active hepatitis B or active hepatitis C;\n* Those who have used immune cell therapy in the past;\n* History of severe cardiovascular disease, such as severe cardiac rhythm or conduction abnormalities (ventricular arrhythmia requiring clinical intervention, II.\\~III. degree atrioventricular block, etc.), myocardial infarction, history of coronary artery bypass surgery, heart failure, New York College of Cardiology (NYHA) grade II or above, left ventricular ejection fraction (LVEF) ≤50% and thrombosis found, male QTcF \\>450msec or female QTcF \\>470msec, etc.;\n* Subjects with a history of severe cerebrovascular diseases such as stroke;\n* Need to combine with other anti-tumor therapies (including various radiotherapy, chemotherapy, immunotherapy, targeted therapy, traditional Chinese medicine therapy, etc.);\n* Previous clear history of neurological or psychiatric disorders, including epilepsy or dementia;\n* In the opinion of the investigator, the subject has other reasons that make it unsuitable to participate in this clinical study.",{"count":344,"type":20},24,[54],"This study is an open-label, dose-escalation, investigator-initiated phase I interventional clinical study. To evaluate the safety, tolerability and preliminary efficacy of SCT-001 CAR-T cell injection in subjects with relapsed and refractory epithelial ovarian, fallopian tube and peritoneal cancer, and to explore the pharmacokinetic characteristics, biomarker changes and immunogenicity of SCT-001 CAR-T cell injection in subjects with relapsed and refractory epithelial ovarian, fallopian tube and peritoneal cancer.\n\nIn this study, two trial cohorts were set up, cohort 1 was the intraperitoneal route of administration, and the subjects enrolled in cohort 1 needed to meet the conditions for intraperitoneal administration ((1) the subject had a large amount of ascites, (2) the subject was suitable for peritoneal catheterization, (3) the subject had no severe abdominal adhesions, and (4) the subject agreed to undergo intraperitoneal surgical catheterization for intraperitoneal administration); Cohort 2 is the intravenous route.",[177,26,210],"2025-02-20",{"date":350,"type":33},"2025-02-26",{"date":352,"type":20},"2025-06-01",{"date":354,"type":20},"2030-06-01",{"name":356,"class":357},"Shanghai Gynecologic Oncology Group","OTHER_GOV",{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":365,"targetDuration":4,"studyType":21,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":374,"leadSponsor":376,"locationsCount":41},"100548436","phase-2-rc48-treatment-for-platinum-sensitive-recurrent-ovarian-cancer-with-her2-expression-100548436","NCT06420973","RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression","A Single-arm, Multicenter, Phase II Study of RC48 Plus Platinum With or Without Bevacizumab in the Treatment of HER-2 Expression Platinum-Sensitive Recurrent Ovarian Cancer","Inclusion Criteria:\n\n* Female subjects aged from 18 to 75 years old;\n* Pathology confirmed the diagnosis of primary epithelial ovarian\u002Ffallopian tube\u002Fperitoneal carcinoma;\n* Previous treatment lines ≥1 and ≤4, first-line treatment may include maintenance therapy after complete clinical or pathological response;Previously not receiving targeted HER2 drug therapy (including monoclonal antibodies and ADC drugs)\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial entry;\n* Disease must be measurable by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1);\n* Estimated life expectancy of more than 3 months;\n* Local laboratory confirmed HER2 expression: IHC 1+, 2+, or 3+; Subjects were able to provide samples of the primary or metastatic site of the tumor for HER2 detection（Paraffin blocks, paraffin embedded sections or fresh tissue sections ）\n* Adequate haematological, hepatic and renal functions defined by the protocol;\n* Negative blood pregnancy test at Screening for women of childbearing potential; Highly effective contraception for female subjects if the risk of conception exists;\n\nExclusion Criteria:\n\n* The pathological type is non epithelial ovarian\u002Ffallopian tube\u002Fperitoneal cancer or metastatic ovarian cancer;\n* The patient has ≥ grade 2 peripheral neuropathy;\n* Patients with active bleeding or pathological conditions with high risk of bleeding, such as known hemorrhagic diseases, coagulation disorders, or tumors involving large blood vessels;\n* Suffering from central nervous system metastasis and\u002For cancerous meningitis. Except for stable brain metastases; 5.The toxicity caused by previous anti-tumor treatments has not yet recovered to CTCAE (version 5.0) level 0-1 (excluding 2nd degree hair loss);\n* Patients who require parenteral hydration or nutrition and have evidence of partial intestinal obstruction or perforation;\n* Except for patients with primary endometrial cancer or a history of primary endometrial cancer, unless all of the following conditions are met: stage not greater than I-B stage; No more than superficial muscle infiltration, no vascular or lymphatic infiltration; No poorly differentiated subtypes, including papillary fluid, clear cells, or other FIGO grade 3 lesions;\n* For patients undergoing cell reduction surgery before treatment, if combined with bevacizumab, they must wait for at least 28 days before starting the treatment with bevacizumab;\n* Have undergone major surgery within 4 weeks prior to the start of study administration and have not fully recovered;\n* A large amount of pleural or ascitic fluid accompanied by clinical symptoms or requiring symptomatic treatment;\n* Within 30 days of initial medication or expected to receive attenuated live vaccines during the study period;\n* Serious arterial\u002Fvenous thrombotic events or cardiovascular and cerebrovascular accidents that occurred within one year prior to drug administration were studied;\n* There are systemic diseases that have not been controlled stably according to the judgment of the researcher, including diabetes, liver cirrhosis (Child Pugh Class B or C), interstitial pneumonia, obstructive pulmonary disease, etc;\n* Clinically significant cardiovascular disease patients(According to the specific requirements of the plan);\n* Individuals with active autoimmune diseases or immunodeficiency, or a history of the aforementioned conditions, including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, rheumatoid arthritis, inflammatory bowel disease, pituitary inflammation, vasculitis, nephritis, etc., shall not be included. The following exceptions apply: Patients with a history of autoimmune hypothyroidism who have received thyroid hormone replacement therapy may be included in the study. Patients with type 1 diabetes whose blood sugar can be controlled after treatment with insulin administration scheme can participate in this study;\n* Subjects with a history of other malignant tumors within five years (excluding complete treatment for in situ cervical cancer, basal cell carcinoma, or squamous cell carcinoma skin cancer);\n* Patients with congenital or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA ≥ 2000 IU \u002F ml), hepatitis C (HCV antibody positive and HCV-RNA higher than the detection limit of the analytical method), or co infection of hepatitis B and hepatitis C;\n* Severe infection (e.g. need for intravenous antibiotics, antifungal or antiviral drugs) occurred within 4 weeks before the first administration, or fever (\\>38.5%) of unknown reason occurred during the screening period\u002Fbefore the first administration；\n* Currently participating in intervention clinical research treatment, or receiving other investigational drugs or research instruments within 4 weeks prior to the first administration; Not fully recovered from toxicity and\u002For complications caused by any intervention measures prior to initial administration (i.e. ≤ level 1 or reaching baseline, excluding fatigue or hair loss);\n* Has a clear history of allergies and may have potential allergies or intolerance to the investigational drug and its similar biological agents;\n* Individuals with a history of abuse of psychotropic substances who are unable to quit or have mental disorders;",{"count":366,"type":20},54,[23],"The purpose of this study is to evaluate the efficacy, safety, and quality of life scores of patients with HER2-expressing platinum-sensitive recurrent epithelial ovarian cancer treated with the combination therapy regimen of RC48 plus platinum with or without bevacizumab.",[27,26,28],"2024-05-16",{"date":372,"type":33},"2024-05-20",{"date":370,"type":20},{"date":375,"type":20},"2027-09-17",{"name":377,"class":40},"Peking University Cancer Hospital & Institute",{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":21,"phases":387,"briefSummary":388,"conditions":389,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":41},"100426556","phase-2-a-study-of-maintenance-dcvacovca-after-first-line-chemotherapy-added-standard-of-care-100426556","NCT04834544","A Study of Maintenance DCVAC\u002FOvCa After First-line Chemotherapy Added Standard of Care","A Randomized, Double-blind, Placebo-controlled, Preliminary Verifying Study About Safety and Efficacy of Maintenance DCVAC\u002FOvCa After First-line Chemotherapy Added to Standard of Care in Patients With Newly Diagnosed FIGO III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.","Inclusion Criteria:\n\n1. Eighteen years of age or older at the time written informed consent is obtained\n2. Newly diagnosed, histologically confirmed FIGO stage III or IV EOC (high-grade serous or high-grade endometrioid)\n3. After primary debulking surgery or after interval debulking surgery; residual disease after surgery with optimal resection as R0 or R1 (R0 is defined as no macroscopic residual disease, R1 is defined as macroscopic residual disease with a maximal diameter of \\\u003C1 cm)\n4. Known BRCA status; if BRCA mutation status not known, results of BRCA testing must be available before randomization\n5. Laboratory criteria:\n\n   5.1. White blood cells \\>4000\u002Fmm3 (4.0×109\u002FL) 5.2. Neutrophil count \\>1500\u002Fmm3 (1.5×109\u002FL) 5.3. Hemoglobin ≥8 g\u002FdL (80 g\u002FL) 5.4. Platelet count ≥100,000\u002Fmm3 (100×109\u002FL) 5.5. Total bilirubin \\\u003C2× upper limit of normal (ULN) (benign hereditary hyperbilirubinemias, e.g., Gilbert's syndrome, are permitted) 5.6. Serum alanine aminotransferase, aspartate aminotransferase, and creatinine \\\u003C2×ULN 5.7. Blood urea nitrogen \\\u003C2×ULN\n6. Adequate coagulation parameters:\n\n   6.1. Activated partial thromboplastin time ≤1.5×ULN 6.2. International normalized ratio ≤1.5\n7. ECOG performance status 0-2\n8. Patients of child-bearing potential and their partners who are sexually active must agree to the use of 2 highly effective forms of contraception from the patient's signing of the ICF until 6 months after the last\u002Ffinal dose of first-line Pt-based adjuvant chemotherapy or IMP, whichever occurs later:\n\n   a. Condom with spermicide and one of the following:\n   * Oral contraceptive or hormonal therapy (e.g., hormone implants)\n   * Placement of an intra-uterine device (IUD)\n\n   Acceptable non-hormonal birth control methods include:\n   1. Total sexual abstinence from the patient's signing of the ICF until 6 months after the last\u002Ffinal dose of first-line Pt-based adjuvant chemotherapy or IMP, whichever occurs later\n   2. Vasectomized sexual partner plus male condom with spermicide and participant assurance that partner received post-vasectomy confirmation of azoospermia\n   3. Tubal occlusion plus male condom with spermicide\n   4. IUD plus male condom with spermicide. Provided coils are copper-banded.\n\n   Acceptable hormonal methods include:\n   1. Etonogestrel implants (e.g., Implanon, Norplan) plus male condom with spermicide\n   2. Normal and low dose combined oral pills plus male condom with spermicide\n   3. Norelgestromin\u002Fethinyl estradiol transdermal system plus male condom with spermicide\n   4. Intravaginal device plus male condom with spermicide (e.g., ethinyl estradiol and etonogestrel)\n   5. Cerazette (desogestrel) plus male condom with spermicide. Cerazette is currently the only highly efficacious progesterone-based pill.\n9. Signed informed consent and ability to comprehend its content\n\nExclusion Criteria:\n\n1. Non-epithelial ovarian carcinoma or mixed epithelial histology\n2. Borderline tumors (tumors of low malignant potential)\n3. First-line Pt-based adjuvant chemotherapy already started after surgery\n4. Intention to treat with intraperitoneal chemotherapy\n5. Previous or concurrent radiotherapy to the abdomen and pelvis\n6. Major surgery (with the exception of debulking surgery) within 3 weeks before informed consent signature or patient has not recovered from any effects of any major surgery\n7. Malignancy other than EOC, except malignancy that has been in complete remission for a minimum of 3 years and except carcinoma in situ of the cervix or non-melanoma skin carcinomas that have been definitively treated\n8. Use of any immunotherapy in the past (e.g., anti-PD-1\u002FPD-L1 or other immune checkpoint inhibitors, therapeutic vaccines, adoptive cell therapy, cytokines); in case of uncertainty, discuss with the medical monitor\n9. Symptomatic uncontrolled brain or leptomeningeal metastases. A scan to confirm the absence of brain metastases is not required. Patients with spinal cord compression may be considered if they have received definitive treatment for this and evidence of clinically stable disease for 28 days.\n10. Co-morbidities:\n\n    10.1. HIV positive 10.2. Active hepatitis B (HBV) and\u002For C (HCV), active syphilis 10.3. Evidence of active bacterial, viral, or fungal infection requiring systemic treatment 10.4. Clinically significant cardiovascular disease including: 10.4.1. Symptomatic congestive heart failure 10.4.2. Unstable angina pectoris 10.4.3. Severe cardiac arrhythmia requiring medication 10.4.4. Uncontrolled hypertension 10.4.5. Myocardial infarction or ventricular arrhythmia or stroke within a 6-month period before inclusion, ejection fraction \\\u003C40% or serious cardiac conduction system disorders, if a pacemaker is not present 10.5. Pericardial effusion of any CTCAE grade 10.6. Severe chronic obstructive pulmonary disease defined as grade C and D according to Global Initiative for Obstructive Lung Disease 10.7. Patients considered a poor medical risk due to other serious, uncontrolled medical disorders, non-malignant systemic diseases or active, uncontrolled infections 10.8. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study treatment, or is not in the best interest of the patient to participate 10.9. Active autoimmune disease requiring treatment 10.10. History of severe forms of primary immune deficiencies 10.11. History of anaphylaxis or other severe reactions following vaccination 10.12. Psychiatric or social conditions which, in the investigator's opinion, would prevent participation in the study\n11. Known hypersensitivity to any constituent of IMP\n12. Systemic immunosuppressive therapy for any reason (except inhaled \u002F intranasal steroids and short-term systemic steroids \\\u003C30 days duration and ≤10 mg prednisone-equivalent per day are allowed)\n13. Participation in a clinical trial using experimental therapy within the last 4 weeks before informed consent signature\n14. Pregnant or breast feeding, or expecting to conceive children within the projected duration of the study treatment\n15. Refusal to sign informed consent",{"count":386,"type":20},75,[23],"This is a randomized, double-blind, placebo-controlled,parallel-group preliminary verifying study about safety and efficacy of maintenance DCVAC\u002FOvCa after first-line chemotherapy added to standard of care in patients with newly diagnosed FIGO III-IV ovarian, fallopian tube, or primary peritoneal carcinoma.",[324,26,28],"2021-04-30",{"date":392,"type":33},"2021-05-03",{"date":394,"type":33},"2021-04-19",{"date":396,"type":20},"2027-04-20",{"name":398,"class":40},"Peking University Third Hospital"]